Amgen Inc.

(NASDAQ Global Select)
Back to all articles
Neutral +10

Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock ...

Company update AI-generated analysis

πŸ“ˆ Amgen closed at $414.87 with an 18.6% six-month return, outperforming Gilead's 8.8% and Biogen's 30.5% relative to the S&P 500.

πŸ’° Amgen pays the largest dividend of the three peers, but this payout is funded by substantial borrowing rather than organic cash flow generation.

πŸ“‰ While Amgen shows a spectacular return on equity, the article attributes much of this performance to leverage rather than underlying business profitability.

🏦 Amgen trades at a forward multiple of 16.94x earnings, making it the most expensive valuation among Biogen, Gilead, and itself.

πŸ“Š Hedge fund holdings for Amgen increased in value to $3.14 billion in Q2 2026, held by 66 funds according to Insider Monkey data.

⚠️ All three companies face the permanent industry challenge of replacing revenue as patents expire, including Amgen's portfolio.

Bullish Signals
  • Amgen posted an 18.6% return over the last six months, outperforming Gilead and Biogen in absolute stock price gains during that period.
  • The company is a dominant blue-chip payer within hedge fund portfolios, indicating strong institutional confidence and liquidity.
Risk Factors
  • Amgen carries substantially more debt than its peers, which inflates its return on equity metric and masks underlying asset profitability.
  • The stock trades at the highest forward multiple (16.94x) among the three compared companies, suggesting a premium valuation relative to Biogen and Gilead.
  • Amgen relies on significant borrowing to fund its largest dividend payout, creating potential financial leverage risks if cash flows tighten.
Full Analysis
Amgen Inc. (NASDAQ:AMGN) closed at $414.87, posting an 18.6% return over the last six months compared to peers Biogen and Gilead. The article highlights that while Amgen reports a spectacular return on equity, this metric is significantly influenced by substantial borrowing rather than organic business profitability. In contrast, Gilead demonstrates superior asset efficiency with a 14.09% return on assets and the highest cash generation in the group, despite reporting a net loss due to acquisition-related charges. Amgen's financial profile includes the largest dividend payout among the three companies, which is funded by its high level of debt. The stock trades at a forward multiple of 16.94x earnings, making it the most expensive of the group compared to Biogen's 13.65x and Gilead's 15.29x. Analysts note that Amgen faces the structural industry challenge of replacing revenue as patents expire, similar to its competitors. Hedge fund data from Q2 2026 shows Amgen held by 66 funds with a combined stake value of approximately $3.14 billion, an increase in investment value from the previous quarter. The article concludes that while Amgen is a blue-chip payer dominating hedge fund portfolios, its valuation and debt structure present a different risk profile compared to the cash-rich but loss-reporting Gilead or the cheap but earnings-collapsed Biogen.